Influence of Lactation on Plasma Phenobarbital Concentrations in Rats

Masahiro Moriyama1, Syoichi Yamashita1, Katsushi Furuno1, Tomoaki Sato2, Haruyo Domoto1, Yasuko Yamatogi3, Hiromu Kawasaki1 and Yutaka Gomita1,*

1 Department of Hospital Pharmacy and 1Child Neurology, Okayama University Medical School, 2–5–1 Shikata-cho, Okayama 700, Japan
2Department of Hospital Pharmacy, Faculty of Medical Sciences, Kyushu University, Fukuoka 812, Japan

Received August 19, 1996 Accepted December 4, 1996

ABSTRACT—The effect of lactation on the pharmacokinetics of phenobarbital (PB) after delivery was studied in female rats. Non-pregnant animals received PB 20 mg/kg/day twice for 6–7 days before mating, during pregnancy and after delivery. Chronic PB did not significantly influence changes in the body weight of rats after delivery. On the first post-delivery day, the plasma PB concentration in the PB-treated rats was significantly higher than that in PB-treated, non-pregnant rats (non-pregnant rats); and thereafter, it gradually decreased until ablactation on the 20th day. After ablactation, plasma PB concentrations gradually returned to the level before delivery. In PB-treated rats, pharmacokinetic parameters (Cmax, AUC0-12) of PB between 0 and 12 hr after a single oral administration were significantly decreased during lactation. These results suggest that PB administered during lactation is transferred in part to offspring through maternal milk.

Keywords: Phenobarbital, Pharmacokinetics, Lactation, Plasma concentration

The number of epileptic women undergoing treatment and who desire children are increasing. These patients should continue to take antiepileptic drugs during pregnancy, delivery and lactation for seizure control.

After delivery, mothers have been encouraged to nourish their children by breast feeding because of the immunological (1), nutritional (2) and psychological (3) advantages of maternal milk. In addition, breast feeding prevents withdrawal symptoms such as vomiting, restlessness, hyperactivity and tremor, which appear in babies delivered from women taking antiepileptic or sedative drugs (4).

Many investigators have reported the influences of antiepileptic drugs on the offspring of epileptic mother (5–8). The frequency of maternal psychomotor seizures increases during early puerperium (9). However, there are few reports describing the pharmacokinetics of antiepileptic drugs in the mother during lactation (10).

We developed a means of measuring plasma phenobarbital (PB) concentrations in small amounts (60 µl) of rat blood, which allows repeated evaluations (11). Using this method, we found that pregnancy itself does not affect the plasma level and pharmacokinetic parameters of PB during chronic treatment when a fixed dosage is given according to maternal body weight (12). In the present study, we examined the pharmacokinetics of PB during lactation in rats.

MATERIALS AND METHODS

Chemicals

PB was purchased from Sigma Chemical Co. (St. Louis, MO, USA). For oral administration, PB was suspended in 0.5% sodium carboxymethylcellulose (CMC). Acetanilide (Wako Pure Chemical Industries, Osaka) was used as an internal standard (IS) and dissolved at a concentration of 2 µg/ml in 50% methanol. All other reagents were of guaranteed grade.

Animals

Female Wistar rats weighing 195 to 210 g at the beginning of the study were obtained from Charles River Japan, Inc. (Atsugi). They were housed in the experimental animal center of Okayama University Medical School at a controlled ambient temperature of 22°C with 60% relative humidity and under a 12-hr light/dark cycle (light on from 7:00).

Experimental procedure

Female rats were divided into 3 groups: a) PB-treated
and undelivered, b) PB-treated and lactating and c) PB-untreated and lactating group. The effect of lactation on the plasma PB level (trough level) before daily administration was compared between groups a and b. In addition, the effect of lactation on the pharmacokinetic parameters following PB administration was studied in groups b and c. Each animal was measured and PB (20 mg/kg) was weighed by gavage to groups a and b twice (at 07:00 and 19:00) every day throughout the experiment. In group c, 0.5% CMC (vehicle) was orally administered according to the same schedule. Before the administration of PB or vehicle at 07:00, blood was collected from the tail vein into 60-μl capillaries, and plasma PB concentrations were measured. When the plasma concentrations of PB reached the steady state (7 to 10 days after starting administration), female and male rats were mated for 5 days.

Each pregnant rat in groups a and b was delivered of 6 to 16 pups. To standardize the amount of lactation, we selected 3 rats, which had given birth to 13 to 16 offspring, for the study of the lactating group. Twenty days after delivery, the pups were weaned.

During early lactation (2–4 days after delivery) and mid lactation (10–11 days after delivery) and after discontinuing of breast feeding (2–3 days after weaning), we examined time-course changes in the plasma PB concentrations from 0 to 12 hr after a single oral administration of PB in both lactating groups b and c. Food was withheld for 12 hr before and throughout this experiment.

Determination of plasma PB level

After centrifugation at 12,000 rpm for 3 min in a hemocrit centrifuge (Compur M 1100; Compur Electronic GmbH, Munich, Germany), 20 μl of plasma with 0.1 μg of IS was passed through a Bond Elut cartridge (1-ml volume, No. 1210-2001; Varian SPP, Harbour City, CA, USA), which was washed twice with 1 ml of methanol and 1 ml of 0.01 M KH₂PO₄. The samples were eluted with 250 μl of methanol. The eluate (20 μl) was applied to a high performance liquid chromatograph (HPLC) system, composed of a pump (type 510; Waters-Millipore, Milford, MA, USA), an automatic sample processor (Type 710B), an ultraviolet monitor (Type 481), and a data module (Type 730). The analytical column was a LiChroCART RP-18e (4 μm particle size, 4 × 125 mm; Cica-Merck Co., Tokyo). The mobile phase was a mixture of acetonitrile/0.01 M KH₂PO₄ (25/75, v/v), the flow rate was 0.8 ml/min, and PB was detected at 210 nm. The retention times of IS and PB were 4.6 and 7.8 min, respectively.

Pharmacokinetic analysis

Pharmacokinetic parameters were obtained from the PB plasma concentration-time data from each animal, using a personal computer program for nonlinear least squares regression analysis (MULTI) (13). Time at maximal concentration (T_{max}), maximal plasma concentration (C_{max}), area under the plasma concentration-time curve from 0 to 12 hr (AUC_{0-12}) and mean residence time (MRT) were calculated by standard linear trapezoidal integration.

Statistical analyses

Results are expressed as means±S.E.M. Data were statistically evaluated by the unpaired Student’s t-test followed by repeated-measurement analysis of variance (ANOVA) between chronically PB treated, lactating and non-lactating groups. The pharmacokinetic parameters were evaluated by the paired Student’s t-test between the control (no lactation) and three lactation stages (early, mid and after weaning). A value of P<0.05 was considered statistically significant.

RESULTS

Changes in plasma PB concentrations during chronic administration in lactating and non-lactating rats

Daily PB administration did not affect the body weight of lactating and undelivered rats compared with the untreated control (data not shown). Figure 1 shows changes in plasma PB concentrations (before daily administration) in rats with or without lactation that were chronically treated with PB. As evaluated by repeated ANOVA, the difference between chronically PB-treated, lactating and non-lactating groups was significant (F=9.351, P<0.05). On the first day after delivery, the plasma PB concentration in lactating rats was significantly higher than that in undelivered rats. The elevated plasma PB concentration in the delivered group rapidly decreased on the second day after delivery and thereafter, PB concentrations gradually decreased until ablation. PB concentrations of the group from 8 to 22 days after delivery were significantly lower than those of the undelivered groups. After weaning on the 20th day after delivery, maternal plasma PB concentrations gradually returned to levels on the 2nd day after delivery.

Effect of lactation on pharmacokinetics of PB

Figure 2 shows the time-course changes in plasma PB concentrations after a single oral (20 mg/kg, p.o.) administration of PB during early (2–4 days after delivery) lactation. Plasma PB concentrations in both chronically PB-treated and untreated rats rapidly increased to a maximum of 31.2 and 16.2 μg/ml at 1 and 2 hr, respectively,
and then gradually decreased.

During mid (10-11 days after delivery) lactation in chronically PB-treated and untreated rats, the plasma PB concentrations rapidly increased to a maximum of 32.8 and 23.3 μg/ml at 2 and 1 hr, respectively, and then decreased faster than in the early stage of lactation (Fig. 3).

Figure 4 shows changes in the plasma PB concentrations following the oral administration of PB (20 mg/kg, p.o.) after ablactation (2-3 days after weaning from the mother). Plasma PB concentrations in chronically PB-treated and -untreated rats rapidly increased to a maximum of 46.2 and 23.9 μg/ml at 2 hr, respectively, and then gradually decreased in a manner similar to the time-course changes during early lactation.

Pharmacokinetic parameters of PB in delivered and
lactating rats are shown in Table 1. In mid lactation, \( C_{\text{max}} \), \( \text{AUC}_{0-12} \) and MRT decreased, when compared with the control rats (pre-delivery and non-lactating rats). Both \( C_{\text{max}} \) and \( \text{AUC}_{0-12} \) in lactating rats were significantly lower than those in control rats. In the post-lactation rat, the pharmacokinetic parameters (\( C_{\text{max}}, \text{AUC}_{0-12} \)) were almost at control levels.

**DISCUSSION**

The present study showed that a) chronic PB administration did not affect the body weight of lactating and undelivered rats; b) the plasma concentration of PB decreased gradually during lactation until weaning on the 20th day; c) after ablactation, plasma PB concentrations....
returned to pre-lactation levels and d) the C_{max} and AUC_{0-12} values significantly decreased during lactation. These results suggest that lactation causes a decrease in the plasma PB concentration in rats.

Table 1. Effect of lactation on pharmacokinetic parameters

<table>
<thead>
<tr>
<th>Experimental groups</th>
<th>Treatment</th>
<th>Lactation</th>
<th>T_{max} (hr)</th>
<th>C_{max} (µg/ml)</th>
<th>AUC_{0-12} (µg hr/ml)</th>
<th>MRT (hr)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Untreated</td>
<td>Control (no lactation)</td>
<td>3.0±0.4</td>
<td>26.5±1.8</td>
<td>256.5±21.4</td>
<td>6.1±0.1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Early stage</td>
<td>2.7±1.0</td>
<td>16.6±1.4* (P=0.02)</td>
<td>172.8±11.3* (P=0.05)</td>
<td>6.0±0.2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Middle stage</td>
<td>0.8±0.2* (P=0.02)</td>
<td>21.8±1.1* (P=0.05)</td>
<td>173.8±2.2* (P=0.04)</td>
<td>5.1±0.1* (P=0.03)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>After the weaning</td>
<td>1.9±0.8</td>
<td>24.7±0.3</td>
<td>241.0±5.9</td>
<td>5.7±0.1* (P=0.05)</td>
<td></td>
</tr>
<tr>
<td>20 mg/kg/day Control (no lactation)</td>
<td>1.4±0.1</td>
<td>41.9±2.1</td>
<td>425.3±39.9</td>
<td>4.1±0.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Early stage</td>
<td>2.0±0.5</td>
<td>31.2±1.4* (P=0.01)</td>
<td>314.0±9.0* (P=0.05)</td>
<td>4.9±0.3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Middle stage</td>
<td>1.4±0.1</td>
<td>33.0±1.2* (P=0.02)</td>
<td>268.7±27.2* (P=0.02)</td>
<td>3.9±0.2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>After the weaning</td>
<td>1.9±0.8</td>
<td>47.0±0.7</td>
<td>503.4±10.7</td>
<td>5.7±0.2* (P=0.05)</td>
<td></td>
</tr>
</tbody>
</table>

PB at a single dose of 20 mg/kg was administered orally by gavage to the chronically PB-treated groups. Data indicate means±S.E.M. calculated by the personal computer program MULTI. AUC and MRT values were calculated from 0 to 12 hr after oral administration. Each asterisk indicates a significant difference from the control in each experimental group (paired t-test).

have reported that antiepileptic drug concentrations alter during pregnancy because of physiological changes in hormonal factors (16), renal function (16, 17) and protein binding (16). The decrease in T_{max}, C_{max}, AUC_{0-12} and MRT during lactation and changes in MRT after weaning may be affected by physiological changes caused by pregnancy or by hormonal changes during lactation.

Recently, we reported that pregnancy itself does not affect plasma levels and pharmacokinetic parameters of PB when chronically administered if the dosage is fixed according to maternal body weight, which includes that of the fetus (12). In the present study, plasma PB concentrations in chronic PB-treated rats after delivery gradually decreased when the dosage was fixed according to maternal weight excluding that of the pups. Thus, we calculated the plasma PB concentrations when the dosage was determined according to maternal weight plus that of the pups. This calculation showed that plasma PB concentrations gradually elevated due to the increased weight of the offspring during late lactation (data not shown). Therefore, we corrected the plasma PB concentration using the human milk/plasma ratio of 0.35 reported by Kaneko et al. (18, 19), although we have no data on the milk/plasma ratio of PB concentrations in rats because measuring PB concentrations in rat milk is difficult. From this calculation, the corrected plasma PB concentrations were relatively constant during lactation.

In conclusion, the present study suggests that decreased plasma PB concentrations after delivery and changes in the pharmacokinetics of PB during the lactation in rats result from the transfer of PB to the offspring through maternal milk. The present results also suggest that the
loss of PB during lactation reflects a constant PB concentration in the plasma of the lactating patient.

REFERENCES

8. Seth PK, Allewa FR, Takagi S, Yen-Koo HC and Balazs T: Brain neurotransmitter receptor alterations in offspring of rats exposed to phenobarbital, phenytoin or their combination during pregnancy. Neurontoxiology 8, 45–54 (1987)